地诺单抗售价多少呢？

It is the first drug to be used to inhibit nuclear factor kB receptor activator and osteoporosis and other bone diseases. The binding of RANKL to its receptor RANK on osteoclast precursors is necessary for osteoclast proliferation, maturation, activation and survival. Osteoprotegerin is a soluble form of RANK, an inducible receptor for RANKL, which can interfere with RANK/RANKL binding and inhibit osteoclast activity. In animal experimental models, the use of OPG can reduce bone resorption and increase bone mass. On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA.

How much does denosumab cost?

According to Medical Companion Travel, denosumab currently on the market in the United States is 60mg/1ml tube/box, priced at US$1,169.98, which is relatively expensive and most patients say they cannot afford it. In addition, denosumab produced by the American company Amgen has been launched in Turkey, and its price is much cheaper than in the United States. The specification of denosumab in Turkey is 125mg/1ml tube/box, and the price is equivalent to RMB 3,000. Because of this, it is favored by many patients. If patients want to purchase Turkish denosumab, they can contact Medical Travel. Medical Travel is an overseas medical service organization that can directly contact pharmaceutical companies to help patients purchase authentic Turkish denosumab.

Usage and dosage: (1) Xgeva can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.